A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
This study is for adults with moderate to severe ulcerative colitis, especially those who haven't responded well to previous treatments. We're testing a combination of two medicines, vedolizumab and tofacitinib, to see how effective they are when used together. For the first eight weeks, all participants will receive both medicines. After this initial period, if their condition has improved, they will continue with only vedolizumab for a further 44 weeks. The main goal is to understand how well this combined approach works in helping people with ulcerative colitis. The study will also follow participants for several months after their last dose to check on their health and safety.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
If you have ulcerative colitis (UC), you know it can be a challenging condition to manage. This study is looking into a new way to treat adults who have moderate to severe UC, especially if other treatments haven't worked well for them. We're investigating if combining two existing medicines, vedolizumab and tofacitinib, can be a more effective way to help people feel better.
The study aims to understand how well this combination works and if it can help more people achieve 'remission' – a time when symptoms are much reduced or disappear. After an initial period where both medicines are given together, we'll see if continuing with just one of the medicines (vedolizumab) can maintain these improvements. This is about finding the best strategies to help people living with UC lead more comfortable lives.
It's important to know that this is a 'Phase 4' study. This typically means the medicines involved are already approved for use, but researchers want to learn more about how they work together, in different groups of people, or over longer periods. The goal is always to improve understanding of how to best treat conditions like UC.
النقاط الرئيسية
- Tests a combination of two medicines (vedolizumab and tofacitinib) for ulcerative colitis.
- Aimed at adults with moderate to severe UC who haven't responded to previous treatments.
- Initial 8 weeks of both medicines, then 44 weeks of one if you respond well.
- Study duration up to 76 weeks (about 1.5 years) with follow-up.
- Participation is voluntary; you can withdraw at any time.
من قد يكون مؤهلاً؟
To be considered for this study, you need to be an adult between 18 and 65 years old and have been diagnosed with ulcerative colitis for at least three months. Your UC should be considered moderate to severe at the time of screening.
A key requirement is that you've already tried and not responded well to, stopped responding to, or couldn't tolerate at least one, but no more than two, specific types of medicines called TNF antagonists. If you haven't tried any 'biologic' medicines before, you generally won't be able to join this study, unless specific conditions are met and discussed with the medical team.
Also, if you're currently taking steroid medications, your dose needs to have been stable for at least two weeks before your initial screening appointment. The study also has some rules about colonoscopies and checking for bowel cancer risk, depending on your personal medical history.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you an adult aged between 18 and 65?
- Do you have a confirmed diagnosis of moderate to severe ulcerative colitis?
- Have you tried and not responded well to at least one, but no more than two, TNF antagonist medications?
- If you're on steroids for UC, has your dose been stable for at least 2 weeks?
- Are you able to attend regular appointments and follow the study schedule?
ماذا يتضمن المشاركة؟
If you join this study, it could last for up to 76 weeks, which is about a year and a half. For the first 8 weeks, you will receive both vedolizumab and tofacitinib. These will be given to you as directed by the study team. After these 8 weeks, your progress will be carefully checked. If your condition has improved, you will then continue taking only vedolizumab for another 44 weeks.
Throughout the study, you'll have regular appointments and checks to see how you're responding to the treatment and to monitor your health. These visits will help the doctors understand if the treatment is working and if there are any side effects. Even after you stop taking the study medicine, you'll be followed up for at least 26 weeks (about six months) to ensure your continued well-being. The study will take place in medical centres in the United States and Canada.
المخاطر والفوائد المحتملة
المواقع (49)
- Digestive Health Specialsitsالرمز البريدي المؤكددوثان، الولايات المتحدة· التوظيف
- GI Alliance Sun Cityالرمز البريدي المؤكدمدينة الشمس، الولايات المتحدة· التوظيف
- مركز سيدرز-سايناي الطبيالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة· التوظيف
- Hoag Hospital Newport Beachالرمز البريدي المؤكدنيوبورت بيتش، الولايات المتحدة· التوظيف
- Endoscopic Research Incالرمز البريدي المؤكدأورلاندو، الولايات المتحدة· التوظيف
- Alliance Clinical Research of Tampa, LLCالرمز البريدي المؤكدتامبا، الولايات المتحدة· التوظيف
- Gastroenterology Consultants, P.C.الرمز البريدي المؤكدRoswell, United States· التوظيف
- University of Chicago Medicineالرمز البريدي المؤكدشيكاغو، الولايات المتحدة· التوظيف
- GI Alliance - Illinois Gastroenterology Group - Glenviewالرمز البريدي المؤكدجلينفيو، الولايات المتحدة· التوظيف
- GI Alliance - Illinois Gastroenterology Group LLC - Gurneeالرمز البريدي المؤكدGurnee, United States· التوظيف
- مركز جامعة كانساس الطبيالرمز البريدي المؤكدكانساس سيتي، الولايات المتحدة· التوظيف
- جامعة لويفيلالرمز البريدي المؤكدلويفيل، الولايات المتحدة· التوظيف
أسئلة شائعة
ما هو التهاب القولون التقرحي؟
Ulcerative colitis is a long-term condition where the lining of the large intestine (colon and rectum) becomes inflamed and develops tiny open sores (ulcers).
What are vedolizumab and tofacitinib?
These are types of medicine used to treat ulcerative colitis. Vedolizumab is given through a drip (IV), and tofacitinib is taken as a tablet.
Why combine these two medicines?
Researchers want to see if using both medicines together works better for people with ulcerative colitis, especially those who haven't responded well to other treatments before.
كم من الوقت سأكون في الدراسة؟
If you take part, you could be in the study for up to about a year and a half, with medicine given for up to 52 weeks and follow-up checks after that.
هل يمكنني مغادرة الدراسة في أي وقت؟
Yes, you are free to leave the study at any point, and it won't affect your regular medical care.
كيفية معرفة المزيد
اتصل بتاكيدا
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.